uploads///cash rich companies

How Tax Reform Affected Abbott’s 4Q17 Performance


Feb. 2 2018, Updated 9:03 a.m. ET

Tax reform impact on Abbott’s 4Q17 and future performance

In 4Q17, Abbott Laboratories (ABT) reported $828 million in net losses, which came in at $0.48 per share. The loss was due to the impact of a $1.46-billion charge due to the recent US tax reforms. Its adjusted tax rate in fiscal 4Q17 came in at 16.5%.

In fiscal 2018, Abbott Laboratories expects an adjusted tax rate in the range of 14.5%–15%, primarily due to the impact of tax reform as well as global income mix. The company will now be able to repatriate its overseas cash to the US at a lower tax rate. According to Goldman Sachs, the major US companies below have significant overseas cash flows.

Article continues below advertisement

Initially, the tax reform implications were worrisome for Abbott Laboratories because nearly two-thirds of its operations are outside of the US—and because it has a large amount of debt on its balance sheet due to its big-ticket acquisitions of St. Jude Medical and Alere in 2017. However, these tax reforms are expected ultimately to bring down the company’s tax rate and yield long-term growth.

According to Abbott CEO (chief executive officer) Miles White, the company’s management is “pleased with where tax reform came out.”

White also stated the following: “As a multi-national and a company that had a lot of debt in the last two years because of the acquisitions, I had concerns about some of the structures they were looking at, but it all turned out pretty good. I think it will stimulate a lot of growth and investment in the US.”

For exposure to Abbott Laboratories while diversifying the risks driven by company-specific factors, investors can consider investing in the Vanguard Value ETF (VTV). VTV has ~0.82% of its total portfolio holdings in ABT stock.

Tax benefits reinvestment plans

Abbott Laboratories plans to invest its tax benefits into R&D (research and development). Some of the tax benefits are expected to be invested in manufacturing in the US and in SG&A (selling, general, and administrative) expenses.

By comparison, healthcare peer Johnson & Johnson (JNJ) plans to invest its tax benefits in paying dividends and acquisitions. Merck (MRK) is also upbeat about putting more cash toward higher M&As (mergers and acquisitions). After it sees its tax reform benefits, Medtronic (MDT) plans to repatriate its overseas funds over the next eight years and pay $2 billion–$3 billion costs for the same.


More From Market Realist